The 100% efficacy result from the Phase 3 trial for Lenacapavir is a significant milestone for Gilead Sciences. This demonstrates the drug's potential to outperform existing treatments like Truvada, likely leading to increased market share and revenue. Consequently, this positive development is expected to boost investor confidence and drive the stock price up in the short term.